SCHEMBL1536410

SCHEMBL1536410

O=C(O)/C=C/c1ccccc1OC(F)(F)F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.61
GAA P10253 2/20 0.54
PTGER1 P34995 1/20 0.54
PTGER4 P35408 1/20 0.54
PTGER3 P43115 1/20 0.54
PTGER2 P43116 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.52
NFKB1 P19838 2/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA4 P22748 1/20 0.51
MAPT P10636 3/20 0.50
LMNA P02545 2/20 0.50
PLA2G1B P04054 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
NFE2L2 Q16236 2/20 0.47
TFEB P19484 1/20 0.47
MAOB P27338 2/20 0.47
MAOA P21397 1/20 0.47
KDM4E B2RXH2 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1536411 1.00 HTT (0.61) HTTGAAPTGER1PTGER4PTGER3
SCHEMBL26444947 0.87 HTT (0.46) HTTGAAPTGER1PTGER4PTGER3
SCHEMBL24728219 0.85 KDM4E (0.66) HTTGAANFKB1MAPTLMNA
SCHEMBL7631196 0.85 KDM4E (0.66) HTTGAANFKB1MAPTLMNA
SCHEMBL28550579 0.84 MAOB (0.65) HTTGAASMN1; SMN2MAPTLMNA
SCHEMBL1508468 0.83 NFE2L2 (0.53) GAAMAPTLMNANFE2L2TFEB
SCHEMBL1508460 0.83 NFE2L2 (0.53) GAAMAPTLMNANFE2L2TFEB
SCHEMBL28550581 0.82 MAOA (0.50) HTTGAAPTGER1PTGER4PTGER3
SCHEMBL6023587 0.80 HTT (0.56) HTTGAAPTGER1PTGER4PTGER3
SCHEMBL4086754 0.79 KDM4E (0.49) SMN1; SMN2CA1CA2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313539-A1 Alpha, Beta-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES (CN) 2025-10-09 US disclosed
EP-4553069-A1 ALPHA,ß-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2025-05-14 EP disclosed
CN-119790041-A Alpha, beta-unsaturated amide compounds, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2025-04-08 CN disclosed
CN-117402123-A Alpha, beta-unsaturated amide compounds, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2024-01-16 CN disclosed
WO-2024008166-A1 α,β-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 中国科学院上海药物研究所 2024-01-11 WO disclosed
US-11174230-B2 (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide conjugates as potential anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2021-11-16 US disclosed
US-20210163413-A1 (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2021-06-03 US disclosed
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2019-07-04 US disclosed
US-10278972-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2019-05-07 US disclosed
CN-106187891-B Compound and the preparation method and application thereof with anti-Alzheimer disease effect 南京中医药大学 2019-04-23 CN disclosed
WO-2005051410-A9 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2005-07-28 WO disclosed
WO-2005051410-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-06-09 WO disclosed
EP-1505963-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2005-02-16 EP disclosed
US-20040106559-A1 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-03 US disclosed
WO-2003099274-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO disclosed
WO-2003099274-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO disclosed
EP-1309551-A1 INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2003-05-14 EP disclosed
WO-2002014273-A1 INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS SMITHKLINE BEECHAM P.L.C. (GB) 2002-02-21 WO disclosed
EP-1045833-A1 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER INC. (US) 2000-10-25 EP disclosed
WO-1999035130-A1 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER PHARMACEUTICALS INC. (JP) 1999-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10278972-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them TYMS, TYMP, TPX2 HTT 3232/4885GAA 3943/4885PTGER1 308/4885
US-11174230-B2 (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide conjugates as potential anticancer agents TUBB4A, TUBA4A, MAP4 HTT 2625/4885GAA 1640/4885PTGER1 4652/4885
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 HTT 3232/4885GAA 3943/4885PTGER1 308/4885
US-20040106559-A1 Hepatitis C virus inhibitors HAVCR2, HCCS, RNASE1 HTT 4692/4885GAA 444/4885PTGER1 3456/4885
US-20210163413-A1 (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS TUBB4A, TUBA4A, MAP4 HTT 2625/4885GAA 1640/4885PTGER1 4652/4885
US-20250313539-A1 Alpha, Beta-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF DEGS1, ACAD11, HADHA HTT 1166/4885GAA 1193/4885PTGER1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.